Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mbala-Kingebeni Placide, Aziza Amuri, Di Paola Nicholas, Wiley Michael R, Makiala-Mandanda Sheila, Caviness Katie, Pratt Catherine B, Ladner Jason T, Kugelman Jeffrey R, Prieto Karla, Chitty Joseph A, Larson Peter A, Beitzel Brett, Ayouba Ahidjo, Vidal Nicole, Karhemere Stomy, Diop Mamadou, Diagne Moussa M, Faye Martin, Faye Ousmane, Aruna Aaron, Nsio Justus, Mulangu Felix, Mukadi Daniel, Mukadi Patrick, Kombe John, Mulumba Anastasie, Villabona-Arenas Christian-Julian, Pukuta Elisabeth, Gonzalez Jeanette, Bartlett Maggie L, Sozhamannan Shanmuga, Gross Stephen M, Schroth Gary P, Tim Roger, Zhao Junhua J, Kuhn Jens H, Diallo Boubacar, Yao Michel, Fall Ibrahima S, Ndjoloko Bathe, Mossoko Mathias, Lacroix Audrey, Delaporte Eric, Sanchez-Lockhart Mariano, Sall Amadou A, Muyembe-Tamfum Jean-Jacques, Peeters Martine, Palacios Gustavo, Ahuka-Mundeke Steve
Аннотация
METHODS: We used targeted-enrichment sequencing to produce two coding-complete Ebola virus genomes 5 days after declaration of the EVD outbreak in North Kivu. Subsequent sequencing efforts yielded an additional 46 genomes. Genomic information was used to assess early transmission, medical countermeasures, and evolution of Ebola virus.
FINDINGS: The genomic information demonstrated that the EVD outbreak in the North Kivu and Ituri Provinces was distinct from the 2018 EVD outbreak in Équateur Province of the Democratic Republic of the Congo. Primer and probe mismatches to Ebola virus were identified in silico for all deployed diagnostic PCR assays, with the exception of the Cepheid GeneXpert GP assay.
INTERPRETATION: The first two coding-complete genomes provided actionable information in real-time for the deployment of the rVSVΔG-ZEBOV-GP Ebola virus envelope glycoprotein vaccine, available therapeutics, and sequence-based diagnostic assays. Based on the mutations identified in the Ebola virus surface glycoprotein (GP12) observed in all 48 genomes, deployed monoclonal antibody therapeutics (mAb114 and ZMapp) should be efficacious against the circulating Ebola virus variant. Rapid Ebola virus genomic characterisation should be included in routine EVD outbreak response procedures to ascertain efficacy of medical countermeasures.
FUNDING: Defense Biological Product Assurance Office.